GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (OTCPK:INRLF) » Definitions » Short Interest

Valneva SE (Valneva SE) Short Interest


View and export this data going back to 2013. Start your Free Trial

What is Valneva SE Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Valneva SE's Short Interest

For the Biotechnology subindustry, Valneva SE's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valneva SE's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's Short Interest distribution charts can be found below:

* The bar in red indicates where Valneva SE's Short Interest falls into.


Valneva SE (Valneva SE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (OTCPK:INRLF) » Definitions » Short Interest
Comparable Companies
XPAR:MEDCL XPAR:NANO XPAR:ALSEN XPAR:IPH XPAR:AELIS XPAR:ALCLS XPAR:GNFT XPAR:IVA XPAR:TNG XPAR:ADOC OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
VALN:USA VLA:France AYJ:Germany VLA:Austria
Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Website
https://www.valneva.com
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.